Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Flu Vax Giant Sanofi Defends Corner With $650m Protein Sciences Buy

Executive Summary

In agreeing a $650m+ deal to acquire privately owned Protein Sciences, Sanofi is defending its market dominance in influenza vaccinations by adding an approved non-egg based product. The purchase may also help it defend its position in the section of the market targeting elderly patients, since its current trivalent offering is threatened by a rival quadrivalent product from Seqirus.

You may also be interested in...



Sanofi Starts 2018 As It Means To Go On: More Transactions Expected

This year Sanofi will "begin to make our success sustainable," said CEO Olivier Brandicourt in a 2017 financial earnings broadcast; despite a weak finish to 2017 and lower than expected guidance for this year, Sanofi's chief exec is upbeat.

Adapt Or Die: Sanofi CSO On R&D Challenges Within Unstable Industry

Sanofi's chief scientific officer Gary Nabel, who joined the company in 2012 from the NIH, discusses R&D challenges for Sanofi and the wider pharma industry, and highlights the company's biggest drug development achievements and toughest moments over the last few years.

Commercial Capsules: Soriot, IPOs, Deals And Hemophilia Data

IPOs are up, hemophilia is driving company pipelines, speculation over Pascal Soriot's career plans drive billions from AstraZeneca's market capitalization, Sanofi signs a $650m vaccine deal, private equity bidders up their offer for Stada and earnings season kicks off. Commercial capsule rounds up recent business news and trends reported by sister publication Scrip.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel